Advances in Cancer Immunotherapy™ Regional Education Programs

The Society for Immunotherapy of Cancer's (SITC) Advances in Cancer Immunotherapy™ (ACI) 2019-2020 programs are CME-, CPE-, CNE- and MOC-certified regional educational meetings featuring nearly five hours of engaging cancer immunotherapy education, with more time devoted to each topic than ever before. This 2019-2020 programs also provides online, CME-, CPE-, CNE- and MOC-certified companion activities, which are accessible independently by those unable to attend in-person meetings or serve as helpful references for attendees as they incorporate what they learned into practice.

ACIs are free for healthcare professionals in the clinical setting, students and patient advocates. They are presented by local authorities in tumor immunology and cancer immunotherapy and cover the following topics:

• An introduction to cancer immunotherapy: learn about the basic principles behind cancer immunotherapy
• Immunotherapy in practice: attend sessions on lung cancer, skin cancers, head and neck cancers, genitourinary cancers, hematologic malignancies, and other solid tumors including breast and gynecologic cancers, MSI-high tumors and hepatocellular carcinoma
• An overview of cancer immunotherapy associated toxicities, including uncommon and rare immune-related adverse events (irAEs)
• Barriers in practice: recognize barriers to cancer immunotherapy
• The future of cancer immunotherapy: understand trends, developments, potential approvals and disease states with promising data

Thank you for your interest in attending this program. Due to the continually evolving situation surrounding COVID-19, the 2019–2020 ACI series has been postponed. We will post updates as they become available.

In addition to networking with fellow colleagues, attending ACI programs will teach you how to:

• Treat patients with FDA-approved immunotherapies
• Interpret new clinical data supporting the use of checkpoint inhibitors, CAR T therapies, cytokines, oncolytic viruses and vaccines
• Identify and manage irAEs
• Employ strategies to overcome operational and reimbursement barriers to incorporating immunotherapy into your practice
• Apply foundational knowledge for clinical implementation of SITC’s Cancer Immunotherapy Guidelines
• Anticipate forthcoming immunotherapy trends/treatments/trials and how they impact your patients and practices
• Recognize common and uncommon toxicities in immunotherapy patients and provide solutions/adjustments in treatment to address them

The Society for Immunotherapy of Cancer (SITC) Advances in Cancer Immunotherapy™ (ACI) 2019-2020 programs are CME-, CNE-, CPE- and MOC-certified programs presented by experts in tumor immunology and cancer immunotherapy and are free for healthcare professionals, students and patient advocates.

The 2019–2020 ACI series is jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

The 2019–2020 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech (excluding the Canadian program), Incyte Corporation and Merck & Co., Inc. 

The 2020–2021 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP.